Search results
Showing 61 to 75 of 155 results for ckd
This guideline covers identifying and treating primary hypertension (high blood pressure) in people aged 18 and over, including people with type 2 diabetes. It aims to reduce the risk of cardiovascular problems such as heart attacks and strokes by helping healthcare professionals to diagnose hypertension accurately and treat it effectively.
This quality standard covers preventing, detecting and managing acute kidney injury in adults, young people and children. It describes high-quality care in priority areas for improvement.
View quality statements for QS76Show all sections
Sections for QS76
- Quality statements
- Quality statement 1: Raising awareness in people at risk
- Quality statement 2: Identifying acute kidney injury in people admitted to hospital
- Quality statement 3: Response to acute kidney injury warning stage 2 test result
- Quality statement 4: Response to acute kidney injury warning stage 3 test result
- Quality statement 5: Referral for renal replacement therapy
- Quality statement 6: Clinical review after hospital discharge
- Update information
Evidence-based recommendations on electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease. This involves delivering electrical impulses to weakened muscles using electrodes placed on the skin.
View recommendations for IPG677Show all sections
Evidence based recommendations on patiromer (Veltassa) for treating hyperkalaemia in adults.
of intravenous iron preparations in children with anaemia of chronic kidney disease (CKD), including safety, dosing and...
This guideline covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It includes advice on diagnosis, education and support, blood glucose management, cardiovascular risk, and identifying and managing long-term complications.
Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)
Evidence-based recommendations on sodium zirconium cyclosilicate (Lokelma) for treating hyperkalaemia in adults.
Chronic heart failure in adults: diagnosis and management (NG106)
This guideline covers diagnosing and managing chronic heart failure in people aged 18 and over. It aims to improve diagnosis and treatment to increase the length and quality of life for people with heart failure.
Evidence-based recommendations on imlifidase (Idefirix) for desensitisation treatment before kidney transplant in people with chronic kidney disease.
This guideline covers the assessment for and management of blood transfusions in adults, young people and children over 1 year old. It covers the general principles of blood transfusion, but does not make recommendations relating to specific conditions.
In development [GID-TA11547] Expected publication date: TBC
treatment of cardiovascular risk factors Managing complications: chronic kidney disease, eye disease, gastroparesis, erectile...
Implanting a baroreceptor stimulation device for resistant hypertension
In development [GID-IP1180] Expected publication date: TBC
Etelcalcetide for treating secondary hyperparathyroidism (TA448)
Evidence-based recommendations on etelcalcetide (Parsabiv) for treating secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis.
effectiveness of SGLT2 inhibitors in adults with type 2 diabetes and chronic kidney disease, stratified across different ethnic groups?...